Aspen Neuroscience, Inc. announced that this month it will launch the first patient screening study of its kind, working with multiple clinical screening sites in the U.S. The company’s Trial-Ready Cohort Study is a preliminary step to filing an Investigational New Drug (IND) application with the US Food & Drug Administration for ANPD001, its first…
從這篇文章可以得到什麼：
- 宣布本月將與美國多個臨床篩檢中心合作，啟動首個此類病患篩檢研究。
- The company’s Trial-Ready Cohort Study is a preliminary step to filing an Investigational New Drug (IND) application with the US Food &.
- 訂閱是免費的。
